What SEC filings does Viking Therapeutics, Inc. submit to the SEC?

Viking Therapeutics, Inc. (VKTX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VKTX?

A Form 4 for VKTX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Viking Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VKTX?

The 10-K is Viking Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VKTX SEC filings directly on EDGAR?

You can view all historical Viking Therapeutics, Inc. filings on the SEC EDGAR company page for VKTX. Each filing card on this page links directly to the original SEC document.

How often does Viking Therapeutics, Inc. file with the SEC?

Viking Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VKTX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

VKTX SEC Filing News — Viking Therapeutics, Inc.

Latest SEC filings for Viking Therapeutics, Inc. (VKTX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-28.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective…

Sector: Healthcare Industry: Biotechnology Market Cap: $3.2B CIK: 1607678

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for VKTX currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

VKTX Filing Activity Snapshot 2026-01-05 — 2026-09-28

Insider Transactions (Form 4)

1 buy vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$4.95M

Lian Brian (Director, President & CEO) · 2026-07-29

148,517 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Viking Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 4 open-market sale, 3 compensation award and 1 open-market purchase. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×3: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-08-07

VKTX insider Form 4 filed for equity award, exercise, or tax withholding

Kelly-Gemmell Dorothy Elizabeth (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,333	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	40,800	—	—

Filing: Form 4 (Insider Transaction) Insider: Kelly-Gemmell Dorothy Elizabeth (Director) Shares: 6,333

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-29

VKTX insider Lian Brian (Director, President & CEO) sold 148,517 shares (~$4.95M)

Lian Brian, listed as Director, President & CEO at Viking Therapeutics, Inc., reported an open-market sale of 148,517 VKTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	221,667	—	—
`S`	Open-market sale	148,517	$33.32	$4.95M

Filing: Form 4 (Insider Transaction) Insider: Lian Brian (Director, President & CEO) Shares: 148,517 Est. Value: $4.95M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-29

VKTX insider ZANTE GREG (Chief Financial Officer) sold 21,217 shares (~$710.1K)

ZANTE GREG, listed as Chief Financial Officer at Viking Therapeutics, Inc., reported an open-market sale of 21,217 VKTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	31,667	—	—
`S`	Open-market sale	21,217	$33.47	$710.1K

Filing: Form 4 (Insider Transaction) Insider: ZANTE GREG (Chief Financial Officer) Shares: 21,217 Est. Value: $710.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-29

VKTX insider Mancini Marianna (Chief Operating Officer) sold 18,217 shares (~$609.6K)

Mancini Marianna, listed as Chief Operating Officer at Viking Therapeutics, Inc., reported an open-market sale of 18,217 VKTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	31,667	—	—
`S`	Open-market sale	18,217	$33.47	$609.6K

Filing: Form 4 (Insider Transaction) Insider: Mancini Marianna (Chief Operating Officer) Shares: 18,217 Est. Value: $609.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-03

VKTX insider Form 4 filed for equity award, exercise, or tax withholding

Chen Hubert C (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	190,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Chen Hubert C (Chief Medical Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-03-10

VKTX insider Aubuchon Neil William (Chief Commercial Officer) bought 4,475 shares (~$149.9K)

Aubuchon Neil William, listed as Chief Commercial Officer at Viking Therapeutics, Inc., reported an open-market purchase of 4,475 VKTX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	4,475	$33.50	$149.9K

Filing: Form 4 (Insider Transaction) Insider: Aubuchon Neil William (Chief Commercial Officer) Shares: 4,475 Est. Value: $149.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-01-26

VKTX insider Form 4 filed for equity award, exercise, or tax withholding

Aubuchon Neil William (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	180,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Aubuchon Neil William (Chief Commercial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-01-05

VKTX insider ZANTE GREG (Chief Financial Officer) sold 57,661 shares (~$1.90M)

ZANTE GREG, listed as Chief Financial Officer at Viking Therapeutics, Inc., reported an open-market sale of 57,661 VKTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	41,000	—	—
`A`	Compensation award	32,049	—	—
`S`	Open-market sale	31,961	$32.30	$1.03M
`S`	Open-market sale	13,900	$33.38	$464.0K
`S`	Open-market sale	10,300	$34.24	$352.6K
`S`	Open-market sale	1,500	$32.09	$48.1K
`A`	Compensation award derivative · Stock Option (Right to Buy)	91,000	—	—

Filing: Form 4 (Insider Transaction) Insider: ZANTE GREG (Chief Financial Officer) Shares: 57,661 Est. Value: $1.90M

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Viking Therapeutics, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-07-29

VKTX Form 144 filed for proposed insider sale by BRIAN LIAN (148,517 shares) ~$4.95M

BRIAN LIAN filed a Form 144 with the SEC indicating intent to sell VKTX (Viking Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BRIAN LIAN Shares: 148,517 Est. Value: $4.95M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-29

VKTX Form 144 filed for proposed insider sale by GREG ZANTE (21,217 shares) ~$710.1K

GREG ZANTE filed a Form 144 with the SEC indicating intent to sell VKTX (Viking Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: GREG ZANTE Shares: 21,217 Est. Value: $710.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-29

VKTX Form 144 filed for proposed insider sale by MARIANNA MANCINI (18,217 shares) ~$609.6K

MARIANNA MANCINI filed a Form 144 with the SEC indicating intent to sell VKTX (Viking Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MARIANNA MANCINI Shares: 18,217 Est. Value: $609.6K

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Viking Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-28